Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19746146 | 0.88 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL19744904 | 0.85 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL14993680 | 0.83 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL14918150 | 0.83 | HDAC6 (0.69) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL14993220 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL19746810 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL19745104 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL14918454 | 0.81 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL22574721 | 0.81 | HDAC6 (0.68) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL19745507 | 0.81 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475275-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-05-01 | — | — | EP | claimed |
| WO-2017222951-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | claimed |
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC1 2/4885HDAC8 11/4885 |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC1 2/4885HDAC8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.